2/3/2014 8:36:35 AM
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca (NYSE: AZN) today announced that on February 1, 2014, it completed its acquisition of the entirety of Bristol-Myers Squibb’s interests in the companies’ diabetes alliance. The acquisition gives AstraZeneca ownership of the intellectual property and global rights for the development, manufacture and commercialization of the diabetes business, which in the U.S. includes ONGLYZA® (saxagliptin), KOMBIGLYZE™ XR (saxagliptin and metformin HCl extended release), FARXIGA™ (dapagliflozin), BYETTA® (exenatide), BYDUREON® (exenatide extended-release for injectable suspension), Symlin® (pramlintide acetate) and the investigational agent metreleptin.
Help employers find you! Check out all the jobs and post your resume.
comments powered by